MIMS - February prescribing update
Benlysta (belimumab) is a fully human IgG1 monoclonal antibody specific for soluble human B Lymphocyte Stimulator protein (BLyS). Belimumab does not bind B cells directly, but by binding BLyS, belimumab inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin producing plasma cells.
Benlysta is indicated as add-on therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. ANA titre ≥ 1:80 and/or anti-dsDNA titre ≥ 30 IU/mL) despite standard therapy. Benlysta is contraindicated in patients who have demonstrated anaphylaxis to belimumab.
Picato (ingenol mebutate) is a purified ingenol angelate extracted from the E. peplus plant. The mechanism of action of Picato in solar (actinic